Bone destruction of orbital wall in idiopathic orbital inflammatory pseudotumor:does it always imply malignancy?

AIM:To assess the clinical presentations and outcomes of idiopathic orbital inflammatory pseudotumor(IOIP)patients with orbital wall bone destruction(OWBD)and to propose an expanded classification system that includes bone destruction.METHODS:The study retrospectively reviewed clinical presentations,imaging findings,treatment modalities,and outcomes of six patients diagnosed histopathologically with IOIP and OWBD at the Beijing Tongren Hospital,Capital Medical University between October 2018 and June 2021.RESULTS:Over two years,6(10%)of 60 IOIP patients at our hospital exhibited OWBD,but this may overrepresent severe cases.The cohort consisted of three men and three women,aged 17 to 60y(mean 35.5±16.1y).Presenting symptoms included proptosis,eyelid swelling,decreased visual acuity with pain,and palpable mass.Imaging revealed multiple anatomical structures involved with the medial wall being the most common site of bone destruction.Histopathological examination showed classic type in five patients and sclerosing type in one patient.All patients underwent surgical resection followed by methylprednisolone treatment.Follow-up(mean 30.3±3.1mo)indicated three patients had no recurrence,while others had varying degrees of symptom persistence or recurrence.CONCLUSION:IOIP with bone destruction is a rare but significant subtype that mimics malignancy,leading to potential diagnostic and therapeutic challenges.Our findings suggest that complete surgical resection combined with adjunctive glucocorticoid therapy can yield favorable outcomes.However,larger-scale studies are needed to further optimize therapeutic approaches.

Increased expression of TUBA1C predicts poor prognosis of breast cancer by regulating cell cycle

Background:A kind of tubulin called TUBA1C is implicated in the occurrence and growth of a number of cancers.We mainly investigated the expression,prognostic significance,mechanism and interaction with immune infiltration of TUBA1C in breast cancer patients.Methods:The expression of TUBA1C as well as its associations with clinical traits and prognosis were examined using the Cancer Genome Atlas,DepMap and Human Protein Atlas databases.The primary pathway involved in breast cancer based on TUBA1C was examined using gene set enrichment analysis software,CancerSEA and the GSCALite database.Then,using ssGSEA and Spearman methods,the interaction between TUBA1C and immune cell infiltration was examined.The R package“pRRophetic”investigated the sensitivity of TUBA1C to chemotherapy and targeted treatment drugs.Results:Patients with BC had significantly higher levels of TUBA1C expression.The poor prognosis of breast cancer patients was linked to the increased expression of TUBA1C.The expression of TUBA1C was identified as an independent risk factor for breast cancer by univariate and multivariate Cox regression analysis.An examination of the gene set enrichment analysis and CanerSEA databases revealed that TUBA1C primarily engages in the cell cycle and DNA replication pathways to have a carcinogenic effect.Th2 cells,aDC,Th1 cells,macrophages,NK CD56dim,neutrophils,DC,Treg,pDC,CD8 T cells,mast cells,NK cells and eosinophils were the 13 types of tumor immune infiltrating cells that TUBA1C was associated with by ssGSEA.Additionally,we discovered that TUBA1C was closely associated with a number of chemotherapy and targeted therapy medications.Our findings suggest that TUBA1C is a novel prognostic predictor of breast cancer,related to immune infiltration and drug sensitivity,and may serve as a new target for breast cancer treatment in the future.Conclusion:According to our study,TUBA1C exerts a carcinogenic effect in breast cancer through oncogenic pathway such as the cell cycle and is associated with immune cell infiltration and predicts response to chemotherapy and targeted therapy.